Is Pretreatment Endoscopic Biopsy a Good Predictor of Signet Ring Cell Histology in Gastric Carcinoma?

Piessen, Guillaume; Amielh, D.; Messager, Mathieu; Vinatier, E.; Leteurtre, Emmanuelle; Triboulet, Jean; Mariette, C.

doi:10.1007/s00268-011-1351-9

Cited by 18 publications

(24 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Another limitation is the absence of systematic reassessment of histological slides. Yet, Piessen et al performed a re-assessment by a blinded pathologist on 33 slides of gastric adenocarcinomas in the University Hospital of Lille, France, which was the main centre of the present study (40). There was a high concordance rate of 93.9%.…”

Section: Discussionmentioning

confidence: 82%

Signet Ring Cells and Efficacy of First-line Chemotherapy in Advanced Gastric or Oesogastric Junction Adenocarcinoma

Lemoine

Adenis

Bouché

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 82%

Signet Ring Cells and Efficacy of First-line Chemotherapy in Advanced Gastric or Oesogastric Junction Adenocarcinoma

Lemoine

Adenis

Bouché

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…With respect to SRCs, few studies have evaluated its predictive role for pathCR and survival in patients with esophageal AC, whereas more data are available for the predictive role of SRCs in gastric cancer . Similarly to gastric cancer, in a study reported by our group, tumors from patients with esophageal AC and SRCs had a lower pathCR rate (9% vs 26%) and more frequently had positive margins (24% vs 10%) in comparison with tumors without SRCs.…”

Section: Discussionmentioning

confidence: 84%

Pathological complete response in patients with esophageal cancer after the trimodality approach: The association with baseline variables and survival—The University of Texas MD Anderson Cancer Center experience

Murphy

Xiao

Patel

et al. 2017

Cancer

144

108

View full text Add to dashboard Cite

show abstract

“…Reliability of samples obtained from routine pre-treatment endoscopic biopsies to predict SRC histology has been recently demonstrated by our group [15]. …”

Section: Methodsmentioning

confidence: 99%

Phase II/III multicentre randomised controlled trial evaluating a strategy of primary surgery and adjuvant chemotherapy versus peri-operative chemotherapy for resectable gastric signet ring cell adenocarcinomas – PRODIGE 19 – FFCD1103 – ADCI002

et al. 2013

Self Cite

View full text Add to dashboard Cite

BackgroundA dramatic increase in the incidence of the diffuse form of gastric adenocarcinomas and particularly signet ring cell carcinomas has been observed in Western countries. Evidence is accruing that signet ring cell carcinomas may have inherent chemo resistance leaving many clinicians unsure of the benefits of delaying surgery to pursue a neoadjuvant approach.Methods/designPRODIGE-19-FFCD1103-ADCI002 is a prospective multicentre controlled randomised phase II/III trial comparing current standard of care of perioperative chemotherapy (2x3 cycles of Epirubicin, cisplatin, 5-fluorouracil) with a strategy of primary surgery followed by adjuvant chemotherapy (6 cycles of Epirubicin, cisplatin, 5-fluorouracil) in patients with a stage IB-III gastric signet ring cell tumour. The principal objective of the phase II study (84 patients) is to determine if the experimental arm (primary surgery followed by adjuvant chemotherapy) has sufficient interest in terms of percentage of living patients at 24 months to be evaluated in a phase III trial. If 7 or less patients in the experimental arm are alive at 24 months, phase III will not be initiated. The primary objective of phase III (230 additional patients) is to demonstrate superiority of the experimental arm in terms of overall survival. Secondary endpoints include overall survival at 36 months, disease free survival at 24 and 36 months, R0 resection rates, treatment tolerance, postoperative mortality and morbidity evaluated by Clavien-Dindo severity index, the prognostic impact of positive peritoneal cytology and the assessment of quality of life. An ancillary study will assess the emotional and cognitive impact of surgery and perioperative chemotherapy for both the patient and their partner.DiscussionAs inherent chemo resistance of signet ring cell tumours and delay in definitive surgery may favour tumour progression we hypothesise that a policy of primary surgery followed by adjuvant chemotherapy will improve overall survival compared to a standard perioperative chemotherapeutic strategy. This randomised phase II/III trial is the first dedicated to this histological subtype. Whilst the development of new biomarkers and targeted therapies are awaited, the results of this trial should further help in devising individualised protocols of patient care in a tumour group whose diversity increasingly demands assessment of alternative strategies.Trial registrationClinicalTrials.gov, NCT01717924

show abstract

Is Pretreatment Endoscopic Biopsy a Good Predictor of Signet Ring Cell Histology in Gastric Carcinoma?

Abstract: The presence of signet ring cells in samples obtained from routine pretreatment endoscopic biopsies accurately predicts SRC histology and poor prognosis. The specific therapeutic strategy can consequently be considered from the initial diagnosis.

Cited by 18 publications

References 39 publications

Signet Ring Cells and Efficacy of First-line Chemotherapy in Advanced Gastric or Oesogastric Junction Adenocarcinoma

Signet Ring Cells and Efficacy of First-line Chemotherapy in Advanced Gastric or Oesogastric Junction Adenocarcinoma

Pathological complete response in patients with esophageal cancer after the trimodality approach: The association with baseline variables and survival—The University of Texas MD Anderson Cancer Center experience

Phase II/III multicentre randomised controlled trial evaluating a strategy of primary surgery and adjuvant chemotherapy versus peri-operative chemotherapy for resectable gastric signet ring cell adenocarcinomas – PRODIGE 19 – FFCD1103 – ADCI002

Contact Info

Product

Resources

About